ConductScience.org, home

Paper39375952

Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.

Na JY and 8 others. Cancer Sci, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor. Papers, record 39375952. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375952

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.
PubMed
Journal
Cancer Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Clinical Trial, Phase I
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.55, provisional
iCite
Revised in PubMed
2024-12-05
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Na JYJoo Younghttps://orcid.org/0000-0002-4533-7358
2Jeon JJuyeun
3Huh KYKi Young
4Yu KSKyung-Sang
5Lee SSangmi
6Eom JJaehyun
7Ahn JJinhyung
8You WKWeon-Kyoo
9Oh JJaeseong

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Vascular Endothelial Growth Factor AMajor topic
Antibodies, BispecificMajor topic
Humans
Male
Female
Adult
Middle Aged
Aged
Models, Biological
Body Weight

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Jeju National UniversityPubMed

Source PubMed

Download CSV of grants

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110826130Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.J Pharmacokinet Biopharm1999https://conductscience.org/library/papers/10826130PubMed
221803743DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.Cancer Res2011https://conductscience.org/library/papers/21803743PubMed
337573354Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.J Hematol Oncol2023https://conductscience.org/library/papers/37573354PubMed
439375952Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.Cancer Sci2024https://conductscience.org/library/papers/39375952PubMed
533383646ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.Int J Mol Sci2020https://conductscience.org/library/papers/33383646PubMed
627049350Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.MAbs2016https://conductscience.org/library/papers/27049350PubMed
719620385Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.J Clin Pharmacol2009https://conductscience.org/library/papers/19620385PubMed
815863032Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.Cytokine Growth Factor Rev2005https://conductscience.org/library/papers/15863032PubMed
919649712Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.AAPS J2009https://conductscience.org/library/papers/19649712PubMed
1033593403The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.J Hematol Oncol2021https://conductscience.org/library/papers/33593403PubMed
1129059436Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.J Natl Cancer Inst2017https://conductscience.org/library/papers/29059436PubMed
1218056450Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.Cancer Res2007https://conductscience.org/library/papers/18056450PubMed
139561839Signaling angiogenesis and lymphangiogenesis.Curr Opin Cell Biol1998https://conductscience.org/library/papers/9561839PubMed
1417627537Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.Curr Pharm Des2007https://conductscience.org/library/papers/17627537PubMed
1520167860Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.Am J Pathol2010https://conductscience.org/library/papers/20167860PubMed
1615916729Recombinant approaches to IgG-like bispecific antibodies.Acta Pharmacol Sin2005https://conductscience.org/library/papers/15916729PubMed
1711245282Molecular mechanisms of tumor angiogenesis and tumor progression.J Neurooncol2000https://conductscience.org/library/papers/11245282PubMed
1819030102Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells.PLoS One2008https://conductscience.org/library/papers/19030102PubMed
1921831306Anti-DLL4, a cancer therapeutic with multiple mechanisms of action.Vasc Cell2011https://conductscience.org/library/papers/21831306PubMed
2027110105Weight-based dosing in medication use: what should we know?Patient Prefer Adherence2016https://conductscience.org/library/papers/27110105PubMed

See all 37 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42756177Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.Front Pharmacol2026https://conductscience.org/library/papers/42756177PubMed
39375952Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.Cancer Sci2024https://conductscience.org/library/papers/39375952PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DLL454567PubTator's text mininghttps://conductscience.org/library/genes/54567NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39375952

GET https://conductscience.org/api/papers/v1/39375952/references?page=2